Evidence map›Paper›PMID 25897834›Full record

ArticleTranslational psychiatry2015

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

J M Biernacka, K Sangkuhl, G Jenkins, R M Whaley, P Barman, A Batzler, R B Altman, V Arolt, J Brockmöller, C H Chen and 22 more

Erratum issued 2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 69 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 11 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04179006 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Effects of Nutrients Supplementation in Antidepressant Treated Depressive Disorder Patients

TypeinterventionalSponsorNational Cheng-Kung University HospitalRan2019 to 2023Enrolled120ConditionsDepressive Disorder, MajorArmsLF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)
NCT06073340 terminatednot on this mapstarted 2023, after this paper: background citation

Observational Longitudinal Study of Individuals With Stimulant Use Disorder: Research and Development of a Biosignature

TypeobservationalSponsorUniversity of Texas Southwestern Medical CenterRan2023 to 2025Enrolled72ConditionsStimulant Use, Stimulant-Related Disorder, Healthy
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 11 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Article
  14. Article
  15. Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 16 institutions in 7 countries.

J M Biernacka1] Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA [2] Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
K SangkuhlDepartment of Genetics, Stanford University, Stanford, CA, USA.
G JenkinsDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
R M WhaleyDepartment of Genetics, Stanford University, Stanford, CA, USA.
P BarmanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
A BatzlerDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
R B Altman1] Department of Genetics, Stanford University, Stanford, CA, USA [2] Department of Bioengineering, Stanford University, Stanford, CA, USA.
V AroltDepartment of Psychiatry and Psychotherapy, University of Muenster, Muenster, Germany.
J BrockmöllerDepartment of Clinical Pharmacology, University Göttingen, Göttingen, Germany.
C H ChenDepartment of Psychiatry, Taipei Medical University-Shuangho Hospital, New Taipei City, Taiwan.
K DomschkeDepartment of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany.
D K Hall-FlavinDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
C J Hong1] Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan [2] Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
A IlliDepartment of Psychiatry, School of Medicine, University of Tampere, Tampere, Finland.
Y JiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
O Kampman1] Department of Psychiatry, School of Medicine, University of Tampere, Tampere, Finland [2] Department of Psychiatry, Seinäjoki Hospital District, Seinäjoki, Finland.
T KinoshitaDepartment of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
E Leinonen1] Department of Psychiatry, School of Medicine, University of Tampere, Tampere, Finland [2] Department of Psychiatry, Tampere University Hospital, Tampere, Finland.
Y J Liou1] Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan [2] Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
T MushirodaRIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
S NonenDepartment of Pharmacy, Hyogo University of Health Sciences, Hyogo, Japan.
M K SkimeDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
L WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
B T BauneDepartment of Psychiatry, University of Adelaide, Adelaide, SA, Australia.
M KatoDepartment of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Y L LiuCenter for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan.
V PraphanphojCenter for Medical Genetics Research, Rajanukul Institute, Department of Mental Health, Ministry of Public Health Bangkok, Bangkok, Thailand.
J C StinglResearch Division Federal Institute for Drugs and Medical Devices, Bonn, Germany.
S J Tsai1] Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan [2] Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
M KuboRIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
T E KleinDepartment of Genetics, Stanford University, Stanford, CA, USA.
R WeinshilboumDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · USStanford University · USMayo Clinic in Florida · USNational Yang Ming Chiao Tung University · TWTampere University · FIKansai Medical University · JPRIKEN Center for Integrative Medical Sciences · JPFederal Institute for Drugs and Medical Devices · DEHyogo University of Health Sciences · JPMinistry of Public Health · THNational Health Research Institutes · TWTaipei Medical University-Shuang Ho Hospital · TWThe University of Adelaide · AUUniversity of Göttingen · DEUniversity of Münster · DEUniversity of Würzburg · DE

Funding

MAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4M
PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
INHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9M
NCRR NIH HHS UL1 RR024150NIGMS NIH HHS R01 GM028157NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM6137NIGMS NIH HHS U19 GM061388NIGMS NIH HHS U19 GM61388
6 · The paper itself

Abstract

Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably between patients. The International SSRI Pharmacogenomics Consortium (ISPC) was formed with the primary goal of identifying genetic variation that may contribute to response to SSRI treatment of major depressive disorder. A genome-wide association study of 4-week treatment outcomes, measured using the 17-item Hamilton Rating Scale for Depression (HRSD-17), was performed using data from 865 subjects from seven sites. The primary outcomes were percent change in HRSD-17 score and response, defined as at least 50% reduction in HRSD-17. Data from two prior studies, the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, were used for replication, and a meta-analysis of the three studies was performed (N=2394). Although many top association signals in the ISPC analysis map to interesting candidate genes, none were significant at the genome-wide level and the associations were not replicated using PGRN-AMPS and STAR*D data. The top association result in the meta-analysis of response represents SNPs 5′ upstream of the neuregulin-1 gene, NRG1 (P = 1.20E - 06). NRG1 is involved in many aspects of brain development, including neuronal maturation and variations in this gene have been shown to be associated with increased risk for mental disorders, particularly schizophrenia. Replication and functional studies of these findings are warranted.

Indexed as

AdultAntidepressive AgentsBromodomain Containing ProteinsCell Cycle ProteinsCytoskeletal ProteinsFemaleGenome-Wide Association StudyHumansMajor Depressive DisorderMaleMiddle AgedNerve Tissue ProteinsNeuregulin-1PharmacogeneticsPolymorphism, Single NucleotideProtein Serine-Threonine KinasesAntidepressive AgentsBRD2 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsCytoskeletal ProteinsMCPH1 protein, humanNerve Tissue ProteinsNeuregulin-1NRG1 protein, humanProtein Serine-Threonine KinasesSCN7A protein, humanSelective Serotonin Reuptake InhibitorsSTK39 protein, humanTranscription FactorsVoltage-Gated Sodium Channels

Identifiers

PMID25897834
PMCPMC4462610
OpenAlexW2074495846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.